EASDBeyond's analysis on EASD2026-07-23 — Ascletis claims its oral ASC36_35 FDC outperforms eloralintide/tirzepatide combo in preclinical obesity model, positioning it as a potential next‑generation weight‑loss therapyBrowse the full archive →